Derma Sciences Reports First Quarter 2013 Financial Results
Derma Sciences Reports First Quarter 2013 Financial Results
Net Sales up 23%; Advanced Wound Care Sales up 67% Including 33% Organic Growth
Conference call begins at 11:00 a.m. Eastern time today
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (NAS: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March 31, 2013. Highlights of the first quarter of 2013 and recent weeks include:
- Net sales of $18.8 million, up 23% over the prior-year first quarter; up 12% excluding sales from the April 2012 Total Contact Cast (TCC) acquisition
- Advanced wound care (AWC) product sales of $7.5 million, up 67% over the prior-year first quarter; up 33% excluding TCC sales
- AWC products accounted for 40% of net sales, compared with 29% of net sales in the first quarter of 2012
- Traditional wound care (TWC) product sales of $11.3 million, up 5% over the prior-year first quarter
- Gross margin of 35.7%, up 3.8 percentage points from gross margin of 31.9% in the first quarter of 2012; excluding TCC, gross margin of 33.6%
- Net loss of $6.2 million, or $0.38 per share, compared with a net loss of $2.5 million, or $0.24 per share, in the prior-year first quarter
- Commenced patient enrollment in the second of two Phase 3 trials with DSC127 for the treatment of diabetic foot ulcers
- Signed an agreement with Plexus Ventures to assist exploring strategic alternatives for DSC127 outside of the U.S.
"We are pleased to report another quarter of strong sales and operational results in line with our internal forecast," said Edward J. Quilty, chairman and chief executive officer of Derma Sciences. "Sales of AWC products rose 67% over the prior year, with 33% organic growth, but declined slightly as expected on a sequential basis due to seasonality in the business. The TCC-EZ® total contact cast system continued to perform extremely well, growing 9% over the fourth quarter of 2012. TCC-EZ is becoming an anchor product in our AWC portfolio, yet with market penetration below 2%, there is plenty of room for growth. Our innovative, proprietary, AWC products now account for 40% of our total sales and are driving our gross margin expansion. We expect our organic AWC sales to grow between 30% and 40% in 2013, and our segment contribution to be near break-even in the fourth quarter."
Mr. Quilty continued, "The two Phase 3 trials with our drug candidate DSC127 for diabetic foot ulcer healing are underway with site initiations ongoing. The first trial, a two-arm study with 211 patients in each arm, commenced in February, and the second trial, a three-arm study with 211 patients in each arm, commenced in April. We expect data readout from both trials in the second quarter of 2015. We have also engaged a firm to explore partnering and/or out-licensing opportunities for DSC127 outside of the U.S., and expect this process to be ongoing through the year.
"Sales of our TWC products grew nicely over the prior year, with our first aid products doing well," he added. "Sales in Canada, however, have been impacted by the loss of TWC sales in a very competitive marketplace. In addition, first quarter sales tend to be the softest of all the quarters each year. We expect growth of our TWC products to be between 0 and 2% in 2013."
Net sales for the first quarter of 2013 were $18.8 million, compared with $15.3 million for the first quarter of 2012, an increase of 23%. This included 67% growth in sales of AWC products to $7.5 million from $4.5 million in the prior-year quarter. Excluding TCC sales from both periods, sales of AWC products increased 33%. Sales of TWC products were $11.3 million for the quarter, up 5% over $10.8 million in the prior year, driven by higher sales of first-aid and private-label products, partially offset by lower Canada sales.
Gross profit for the first quarter of 2013 was $6.7 million, or 35.7% of net sales, compared with gross profit for the first quarter of 2012 of $4.9 million, or 31.9% of net sales. The increase in gross margin reflected increased sales of higher-margin AWC products, which accounted for 40% of net sales in the quarter compared with 29% of net sales in the same period last year, and favorable TWC product mix and costs (principally cotton prices).
Selling, general and administrative expense for the first quarter of 2013 was $9.9 million, compared with $6.4 million for the first quarter of 2012. The increase was principally due to higher expenditures associated with advanced wound care growth initiatives, together with higher stock based compensation, TCC-related amortization expense and professional service expense.
Research and development expense for the first quarter of 2013 was $3.0 million, compared with $1.1 million in the first quarter of 2012, with the increase due to expenses associated with preparing for and initiating the DSC127 Phase 3 program.
The net loss for the first quarter of 2013 was $6.2 million, or $0.38 per share, compared with a net loss for the first quarter of 2012 of $2.5 million, or $0.24 per share. The increase in net loss was principally due to higher research and development expense, higher stock-based compensation expense of $1.0 million and $0.5 million of additional expense for amortization of intangible assets, principally related to the TCC acquisition.
As of March 31, 2013, Derma Sciences had cash, cash equivalents and investments of $43.7 million, compared with cash, cash equivalents and investments of $45.8 million as of December 31, 2012.
Conference Call and Webcast
Derma Sciences management will host a conference call to discuss first quarter financial results and answer questions beginning at 11:00 a.m. Eastern time today. In addition, management will provide a business update and discuss recent and upcoming milestones.
To participate in the conference call, dial (888) 563-6275 (domestic) or (706) 634-7417 (international). All listeners should provide the following passcode: 68814353. Individuals interested in listening to the live conference call via the Internet may do so by logging onto the Company's website, www.dermasciences.com.
Following the end of the conference call, a replay will be available through May 22, 2013 and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). All listeners should provide the following passcode: 68814353. The webcast will be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trial in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.
|DERMA SCIENCES, INC. AND SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS|
|Three Months Ended|
|Cost of sales||12,085,281||10,401,206|
|Selling, general and administrative||9,853,085||6,359,090|
|Research and development||2,993,166||1,114,698|
|Total operating expenses||12,846,251||7,473,788|
|Other expense (income), net:|
|Other expense (income), net||94,827||(54,884||)|
|Total other expense (income), net||88,804||(59,963||)|
|Loss before income taxes||(6,230,590||)||(2,537,665||)|
|Income tax expense||14,188||1,236|
|Other Comprehensive (Loss) Income|
|Foreign currency translation adjustment||(49,685||)||79,340|
|Net loss per common share - basic and diluted||$||(0.38||)||$||(0.24||)|
|Shares used in computing net loss per common share - basic and diluted||16,593,677||10,610,111|
|DERMA SCIENCES, INC. AND SUBSIDIARIES|
|CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash and cash equivalents||$||38,453,049||$||41,616,657|
|Accounts receivable, net||6,933,383||7,085,713|
|Prepaid expenses and other current assets||3,118,539||3,209,031|
|Total current assets||65,477,193||69,311,989|
|Equipment and improvements, net||3,147,091||3,304,852|
|Identifiable intangible assets, net||16,486,847||17,128,883|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued expenses and other current liabilities||3,196,972||4,132,934|
|Total current liabilities||7,793,291||8,126,621|
|Deferred tax liability||1,678,093||1,736,299|
|Convertible preferred stock, $.01 par value; 1,468,750 shares|
|authorized; issued and outstanding 73,332 shares at March 31,|
|2013 and December 31, 2012 (liquidation preference of|
|$3,222,368 at March 31, 2013)||733||733|
|Common stock, $.01 par value; shares authorized 25,000,000;|
|issued and outstanding 16,765,347 at March 31, 2013 and|
|16,524,723 at December 31, 2012||167,653||165,247|
|Additional paid-in capital||135,182,428||132,163,083|
|Accumulated other comprehensive income -|
|cumulative translation adjustments||1,539,203||1,588,888|
|Total Stockholders' Equity||90,438,481||93,711,193|
|Total Liabilities and Stockholders' Equity||$||100,202,978||$||103,842,630|
Derma Sciences, Inc.
John E. Yetter, 609-514-4744
Executive Vice President of Finance, CFO
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100
KEYWORDS: United States North America New Jersey
The article Derma Sciences Reports First Quarter 2013 Financial Results originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.